Validating a Markov model of treatment for hepatitis C virus-related hepatocellular carcinoma

Methods of Information in Medicine

Volumn 47, Issue 6, 2008, Pages 529-540

  Ishida, Haku ^a,i   Wong, J B ^b   Hino, K ^c   Kurokawa, F ^d   Nishina, S ^e   Sakaida, I ^e   Okita, K ^f   Tamesa, T ^e   Oka, M ^e   Torimura, T ^g   Sata, M ^g   Takahashi, S ^h   Chayama, K ^h   Inoue, Y ^a  

^a YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^b TUFTS UNIVERSITY   (United States)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d YAMAGUCHI ROSAI HOSPITAL   (Japan)

^e YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f Shimonoseki Kousei Hospital   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h HIROSHIMA UNIVERSITY   (Japan)

ⁱ NONE   (Japan)

Author keywords

Hepatocellular carcinoma; Markov model; Prognosis; Sorvivol rate; Validation

Indexed keywords

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SEX RATIO; SURVIVAL RATE; VALIDATION PROCESS;

AGED; CARCINOMA, HEPATOCELLULAR; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL;

EID: 57749193918     PISSN: 00261270     EISSN: None     Source Type: Journal    
DOI: 10.3414/ME9124     Document Type: Article

References (31)

1. Okita K. Clinical aspects of hepatocellular carcinoma in Japan. Intern Med 2006; 45 (5): 229-233.
2. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10 (2 Suppl 1): S115-20.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399): 1907-1917.
4. Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol 2007; 34 (2 Suppl 1): S12-20.
5. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982; 73 (6): 883-888.
6. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982; 73 (6): 889-897.
7. Ishida H, Inoue Y, Kurokawa F, Hino K, Okita K. Cost-effectiveness of screening program for Hepatitis C virus related hepatocellular carcinoma. Japan Journal of Medical Informatics 2002; 27 (suppl): 139-140.
8. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37 (9): 676-691.
9. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. New York: Wiley-Interscience; 2002.
10. Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006; 26 (6): 680-687.
11. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98 (3): 679-690.
12. Hoshida Y, Shiratori Y, Omata M. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. Liver 2002; 22 (6): 479-485.
13. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19 (11): 1159-1172.
14. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005; 3 (1): 75-84.
15. Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003; 9 (7): 672-681.
16. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101 (4): 422-434.
17. Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 2008; 23 (3): 437-444.
18. Group formed to establish "Guidelines for evidence-based clinical practice for the treatment of liver cancer". Clinical practice guidelines for hepatocellular carcinoma. Tokyo: Kanehara & Co., Ltd.; 2005.
19. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer 2004; 100 (11): 2415-2421.
20. Chevret S, Leporrier M, Chastang C. Measures of treatment effectiveness on tumour response and survival: a multi-state model approach. Stat Med 2000; 19 (6): 837-848.
21. Keiding N, Klein JP, Horowitz MM. Multi-state models and outcome prediction in bone marrow transplantation. Stat Med 2001; 20 (12): 1871-1885.
22. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008; 58 (4): 947-952.
23. Faddy MJ, McClean SI. Markov chain modelling for geriatric patient care. Methods Inf Med 2005; 44 (3): 369-373.
24. Smolen HJ, Cohen DJ, Samsa GP, Toole JF, Klein RW, Furiak NM, et al. Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis. Value Health 2007; 10 (6): 489-497.
25. Vanness DJ, Kim WR. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. Health Econ 2002; 11 (6): 551-566.
26. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3 (4): 419-458.
27. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13 (4): 322-238.
28. Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004; 10 (2 Suppl 1): S46-52.
29. Sugawara Y, Makuuchi M. Living donor liver transplantation: present status and recent advances. Br Med Bull 2005; 75-76: 15-28.
30. Llovet JM, Schwartz M, Fuster J, Bruix J. Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis 2006; 26 (3): 248-253.
31. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007;13 (3): 391-399.